Precision biosciences stock.

Aug 1, 2023 · Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Precision BioSciences (DTIL – Research Report) yesterday and set a price target of $1.40.The company’s shares closed ... Precision BioSciences market cap as of November 07, 2023 is $0.05B . Precision BioSciences market cap history and chart from 2018 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares ...4 ngày trước ... Precision BioSciences Inc (DTIL:NASDAQ CM) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.

Read Next: Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications. Price Action: DTIL stock is up 5.54% at $13.33 during the market session on the last check Thursday. SHARE ...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

Mar 9, 2023 · DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...

Precision BioSciences Inc stock performance at a glance. Check Precision BioSciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. DTIL Stock Performance. USD USD; Previous close: 0.437: 0.437: Day range: 0.44 - 0.470.44 - 0.47Year range: 0 - 10 - 1After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of ...DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of …Aug 8, 2023 · ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues.

Funding. Precision BioSciences has raised a total of. $225.2M. in funding over 5 rounds. Their latest funding was raised on Jun 21, 2022 from a Post-IPO Equity round. Precision BioSciences is registered under the ticker NASDAQ:DTIL . Their stock opened with $16.00 in its Mar 27, 2019 IPO. Precision BioSciences is funded by 26 investors.

Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...

Precision BioSciences Inc Registered Shs's market capitalization is $46.27 M by 120.90 M shares outstanding. Precision BioSciences Stock Snapshot 3.34 In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares closed today at $0.85. Roy ...Dec 4, 2023 · At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...

Specific Internship opportunities for Summer 2024 will be posted in January 2024. Please check back to our careers site for more specific opportunities then. Our …Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and ...31 thg 12, 2022 ... Precision BioSciences. 148 views · 11 months ago ...more ... Cramer: This biotech stock could be worth over $100 billion on an FDA approval.Nov 1, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See today’s best-performing stocks on TipRanks >> The company has a one-year ...13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...

These 4 analysts have an average price target of $6.75 versus the current price of Precision BioSciences at $0.525, implying upside. Below is a summary of how these 4 analysts rated Precision ...

DURHAM, N.C.-June 21, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with …Precision BioSciences presents Q4 figures on March 15. Analysts are expecting losses per share of $0.473. Watch Precision BioSciences stock price move in real-time ahead here.About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing ...Get Precision BioSciences, Inc. (DTIL) real-time share value, investment, rating and financial market information from Capital. Friendly Platforms & Trading today. CFDs are …Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...

These 4 analysts have an average price target of $6.75 versus the current price of Precision BioSciences at $0.525, implying upside. Below is a summary of how these 4 analysts rated Precision ...

Precision BioSciences (DTIL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.19 per share a year ago. These ...

Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS ®- based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. In addition, following the platform-wide …31 thg 12, 2022 ... Precision BioSciences. 148 views · 11 months ago ...more ... Cramer: This biotech stock could be worth over $100 billion on an FDA approval.Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS ®- based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. In addition, following the platform-wide …Precision BioSciences, Inc. 0.3829. -0.0071. -1.82%. DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in ...20 thg 11, 2020 ... Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® ...Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...

Precision BioSciences (NASDAQ:DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a ...Precision BioSciences is slated to present a poster at the 64th ASH Annual Meeting between December 10th and 13th. See why DTIL stock is a Buy.DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...Instagram:https://instagram. dfa international core equityfdoordash stockbest stocks to day tradecybin news Mar 13, 2023 · Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ... best short term and long term disability insuranceagncstock Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors foolocker Nov 28, 2023 · The inducement, part of their Inducement Award Plan, allows the employee to purchase 160,000 shares of Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting ... Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.